Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vivus Inc.

www.vivus.com

Latest From Vivus Inc.

ParaGard TV Spot Misrepresents Contraceptive’s Risks, US FDA Says

‘Untitled’ letter is FDA's third in the past eighteen months to target promotions for women’s health products. In the case of advertisement for CooperSurgical's copper-containing intrauterine device, which is regulated as a drug, the agency took issue with distracting visuals and reliance on superimposed text.

Advertising, Marketing & Sales Ad Complaints

Qsymia Webpage’s ‘3 Times Faster’ Weight-Loss Claims Draw US FDA Ire

Claims that Vivus' obesity drug helps patients lose weight faster than diet and exercise alone are false and misleading because the clinical studies were not designed to evaluate the rate of weight loss over time, Office of Prescription Drug Promotion says in untitled letter; Vivus says it is finalizing revisions to its promotions.

Advertising, Marketing & Sales Enforcement

Can Vivus Get Away Without Outcomes Study Of Obesity Drug Qsymia?

Fixed-dose combination of phentermine and topiramate is FDA-approved for chronic, long-term use, but the average duration in the real world is only about 2.1 months, which is reassuring for Qsymia’s cardiovascular safety, according to a new retrospective claims study.

Clinical Trials Cardiovascular

Finance Watch: Opko's Stock Halted As Nasdaq Awaits An Explanation For SEC Pump-And-Dump Lawsuit

Public Company Edition: An SEC complaint alleges that the company, Opko CEO Frost and co-defendants bought penny stocks, pumped up their value, then dumped shares for sizeable profits. Also, Pfizer and Retrophin float debt offerings, while Zealand sells royalties and milestone fees to raise cash.

Financing Regulation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Gynecological, Urological
  • Metabolic Disorders
  • Respiratory, Pulmonary
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Vivus Inc.
  • Senior Management
  • Thomas B King, Interim CEO
    Mark K Oki, CFO & Chief Accounting Officer
    Deborah W Larsen, PhD, Chief Commercial Officer
    John L Slebir, SVP, Bus. Dev. & General Counsel
    Santosh T Varghese, MD, CMO
  • Contact Info
  • Vivus Inc.
    Phone: (650) 934-5200
    900 E. Hamilton Ave
    Suite 550
    Campbell, CA 95008
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register